SUZANE KIOKO ONO

(Fonte: Lattes)
Índice h a partir de 2011
11
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2019 ×

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • conferenceObject
    Novel HBV capsid assembly modulator inhibits pregenomic RNA encapsidation by accelerating capsid assembly kinetics and disrupting core protein dephosphorylation
    (2019) BASSIT, Leda; VERMA, Kiran; ONO, Suzane Kioko; COX, Bryan; AMBLARD, Franck; SCHINAZI, Raymond F.
  • article 83 Citação(ões) na Scopus
    Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
    (2019) SHAH, Neil D.; VENTURA-COTS, Meritxell; ABRALDES, Juan G.; ALBORAIE, Mohamed; ALFADHLI, Ahmad; ARGEMI, Josepmaria; BADIA-ARANDA, Ester; ARUS-SOLER, Enrique; BARRITT, A. Sidney; BESSONE, Fernando; BIRYUKOVA, Marina; CARRILHO, Flair J.; FERNANDEZ, Marlen Castellanos; GUIRIDI, Zaily Dorta; KASSAS, Mohamed El; ENG-KIONG, Teo; FARIAS, Alberto Queiroz; GEORGE, Jacob; GUI, Wenfang; THURAIRAJAH, Prem H.; HSIANG, John Chen; HUSIC-SELIMOVIC, Azra; ISAKOV, Vasily; KARONEY, Mercy; KIM, Won; KLUWE, Johannes; KOCHHAR, Rakesh; DHAKA, Narendra; COSTA, Pedro Marques; PHARM, Mariana A. Nabeshima; ONO, Suzane K.; REIS, Daniela; RODIL, Agustina; DOMECH, Caridad Ruenes; SAEZ-ROYUELA, Federico; SCHEURICH, Christoph; SIOW, Way; SIVAC-BURINA, Nadja; TRAQUINO, Edna Solange dos Santos; SOME, Fatma; SPRECKIC, Sanjin; TAN, Shiyun; VOROBIOFF, Julio; WANDERA, Andrew; WU, Pengbo; YACOUB, Mohamed; YANG, Ling; YU, Yuanjie; ZAHIRAGIC, Nerma; ZHANG, Chaoqun; CORTEZ-PINTO, Helena; BATALLER, Ramon
    BACKGROUND & AIMS: Despite recent advances in treatment of viral hepatitis, liver-related mortality is high, possibly owing to the large burden of advanced alcohol-related liver disease (ALD). We investigated whether patients with ALD are initially seen at later stages of disease development than patients with hepatitis C virus (HCV) infection or other etiologies. METHODS: We performed a cross-sectional study of 3453 consecutive patients with either early or advanced liver disease (1699 patients with early and 1754 with advanced liver disease) seen at 17 tertiary care liver or gastrointestinal units worldwide, from August 2015 through March 2017. We collected anthropometric, etiology, and clinical information, as well as and model for end-stage liver disease scores. We used unconditional logistic regression to estimate the odds ratios for evaluation at late stages of the disease progression. RESULTS: Of the patients analyzed, 81% had 1 etiology of liver disease and 17% had 2 etiologies of liver disease. Of patients seen at early stages for a single etiology, 31% had HCV infection, 21% had hepatitis B virus infection, and 17% had nonalcoholic fatty liver disease, whereas only 3.8% had ALD. In contrast, 29% of patients seen for advanced disease had ALD. Patients with ALD were more likely to be seen at specialized centers, with advanced-stage disease, compared with patients with HCV-associated liver disease (odds ratio, 14.1; 95% CI, 10.5-18.9; P < .001). Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. These patients had significantly more visits to health care providers, with more advanced disease, compared with patients without excess alcohol use. The mean model for end-stage liver disease score for patients with advanced ALD (score, 16) was higher than for patients with advanced liver disease not associated with excess alcohol use (score, 13) (P < .01). CONCLUSIONS: In a cross-sectional analysis of patients with liver disease worldwide, we found that patients with ALD are seen with more advanced-stage disease than patients with HCV-associated liver disease. Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. Early detection and referral programs are needed for patients with ALD worldwide.
  • article 4 Citação(ões) na Scopus
    Long-term virological and adherence outcomes to antiviral treatment in a 4-year cohort chronic HBV study
    (2019) ABREU, Rodrigo M.; BASSIT, Leda C.; TAO, Sijia; JIANG, Yong; FERREIRA, Aline S.; HORI, Patricia Ca; GANOVA-RAEVA, Lilia M.; KHUDYAKOV, Yury; SCHINAZI, Raymond F.; CARRILHO, Flair J.; ONO, Suzane K.
    Background: Chronic hepatitis B (CHB) treatment adherence has been poorly studied worldwide. We evaluated long-term virological and adherence outcomes to antiviral treatment in CHB patients. Methods: A prospective 183 Brazilian CHB patient cohort treated with monotherapy or combination adefovir dipivoxil, entecavir, lamivudine and/or tenofovir disoproxil fumarate was studied in a reference tertiary centre. Treatment adherence was evaluated by a validated questionnaire named 'Assessment of Adherence to Antiviral Therapy Questionnaire' (CEAT-HBV) within three yearly periods (2010/2011, 2013/2014 and 2014/2015). Results: CEAT-HBV identified 43% (79/183) patients with non-adherence to antiviral treatment and among them, 67% (53/79) were viral load positive. The main causes associated with non-response to antiviral treatment were drug resistance variants followed by non-adherence, insufficient treatment duration and other causes. Single-dose pharmacokinetics demonstrated 35% (23/65) antiviral non-adherence. 2 years after the first assessment, the CEAT-HBV indicated that 71% (101/143) of subjects adhered to treatment (per-protocol population). However, 21% (40/183) of the patients could not be evaluated and were excluded. The main reasons for exclusion were death (20/183), 11 out 20 deaths due to hepatocellular carcinoma. HBV booklet was used for medical education. The third CEAT-HBV assessment (2014/2015) showed that 83% (112/135) patients were compliant with treatment adherence (per-protocol population). Long-term evaluation showed that adherence rate based on CEAT-HBV continue to increase after 4-years (P<0.001). Conclusions: The results highlight the importance of CHB therapy adherence assessment monitoring. Long-term adherence outcomes were dynamic and it is possible to increase the migration rate to adherence/HBV-DNA-negative group.